News

May 18, 2020May 18, 2020

PTI-125 Fails to Lower Alzheimer’s Protein Levels in Phase 2 Trial

News

Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from ... Read more

May 11, 2020June 30, 2020

Potential Agitation Treatment, AXS-05, Shows Efficacy and Safety in Phase 2/3 Trial

News

Axsome Therapeutics‘ investigational oral therapy AXS-05 significantly and rapidly lessened agitation in patients with Alzheimer’s disease, top-line results from a Phase 2/3 trial show. The therapy also was found to be generally ... Read more

May 4, 2020May 4, 2020

Large Study Finds No Evidence That Low-dose Aspirin Reduces Alzheimer’s Risk

News

Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The results were published in Neurology in a ... Read more

April 27, 2020April 27, 2020

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

News, syndicated

While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in ... Read more

April 27, 2020April 27, 2020

FDA Filing of Alzheimer’s Therapy Aducanumab Delayed to Late 2020, Biogen Says

News

Biogen is pushing back the submission of aducanumab, its investigational treatment for Alzheimer’s disease, to the U.S. Food and Drug Administration (FDA) to the third quarter of this year ... Read more

April 20, 2020April 20, 2020

Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path

News

Data from Lundbeck’s Phase 2 and 3 clinical trials of idalopirdine in Alzheimer’s patients, will be made available to researchers worldwide through the Critical Path for Alzheimer’s Disease (CPAD) consortium database, held ... Read more

April 13, 2020May 14, 2020

Phase 2/3 Trial of Treatment for Agitation in Alzheimer’s to Conclude Early

News

Axsome Therapeutics is planning to complete its ADVANCE-1 clinical trial, evaluating AXS-05 as a treatment for agitation in Alzheimer’s disease, a few months earlier to ensure the safety of study ... Read more

April 6, 2020April 6, 2020

At-home Activities Offered for Alzheimer’s Patients During COVID-19 Pandemic

News

Because the COVID-19 pandemic has many people staying at home, the Alzheimer’s Foundation of America (AFA) has suggestions about activities to help patients and their families stay active and ... Read more

April 3, 2020April 3, 2020

Trial of Oral Anavex 2-73 in Early Alzheimer’s to Continue with Adjustments

News

Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance ... Read more

March 30, 2020March 30, 2020

Blood Pressure Treatment May Aid Cognition in Very Early Alzheimer’s

News

A new analysis of data from a Phase 3 clinical trial testing the blood pressure medication nilvadipine supports evidence that its use helps to slow cognitive decline in Alzheimer’s patients with very mild, very ... Read more

Pin It on Pinterest